Imaging Characteristics of CNS Neuroblastoma-FOXR2: A Retrospective and Multi-Institutional Description of 25 Cases

BACKGROUND AND PURPOSE: The 5th edition of the World Health Organization Classification of CNS tumors defines the CNS neuroblastoma FOXR2 in the group of embryonal tumors. Published clinical outcomes tend to suggest a favorable outcome after resection, craniospinal irradiation, and chemotherapy. This multicenter study aimed to describe imaging features of CNS neuroblastoma-FOXR2, which have been poorly characterized thus far. MATERIALS AND METHODS: On the basis of a previously published cohort of tumors molecularly classified as CNS neuroblastoma-FOXR2, patients with available imaging data were identified. The imaging features on preoperative MR imaging and CT data were recorded by 8 experienced pediatric neuroradiologists in consensus review meetings. RESULTS: Twenty-five patients were evaluated (13 girls; median age, 4.5 years). The tumors were often large (mean, 115 [ SD, 83] mL), showed no (24%) or limited (60%) perilesional edema, demonstrated heterogeneous enhancement, were often calcified and/or hemorrhagic (52%), were always T2WI-hyperintense to GM, and commonly had cystic and/or necrotic components (96%). The mean ADC values were low (687.8 [SD 136.3] × 10−6 mm2/s). The tumors were always supratentorial. Metastases were infrequent (20%) and, when present, were of nodular appearance and leptomeningeal. CONCLUSIONS: In our cohort, CNS neuroblastoma FOXR2 tumors showed imaging features suggesting high-grade malignancy and, at the same time, showed characteristics of less aggressive behavior. There are important differential diagnoses, but the results of this study may assist in considering this diagnosis preoperatively.

[1]  H. Brisse,et al.  Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication , 2021, American Journal of Neuroradiology.

[2]  M. Shago,et al.  Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. , 2021, The Lancet. Child & adolescent health.

[3]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[4]  M. Kool,et al.  Therapeutic implications of improved molecular diagnostics for rare CNS-embryonal tumor entities: results of an international, retrospective study. , 2021, Neuro-oncology.

[5]  David T. W. Jones,et al.  Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation , 2021, Acta Neuropathologica Communications.

[6]  D. Clements.  Project , 2003, about.

[7]  U. Schüller,et al.  Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas. , 2020, Journal of neuropathology and experimental neurology.

[8]  J. Zeng,et al.  Case Report: A Unique Case of Pediatric Central Nervous System Embryonal Tumor Harboring the CIC–LEUTX Fusion, Germline NBN Variant and Somatic TSC2 Mutation: Expanding the Spectrum of CIC-Rearranged Neoplasia , 2020, Frontiers in Oncology.

[9]  Qiguang Wang,et al.  The Survival and Prognostic Factors of Supratentorial Cortical Ependymomas: A Retrospective Cohort Study and Literature-Based Analysis , 2020, Frontiers in Oncology.

[10]  E. Miele,et al.  Central nervous system high-grade neuroepithelial tumor with BCOR alteration (CNS HGNET-BCOR)—case-based reviews , 2020, Child's Nervous System.

[11]  K. Ohshima,et al.  Central nervous system neuroblastic tumor with FOXR2 activation presenting both neuronal and glial differentiation: a case report , 2020, Brain Tumor Pathology.

[12]  S. Bens,et al.  Age and DNA-methylation subgroup as potential independent risk factors for treatment stratification in children with Atypical Teratoid/Rhabdoid Tumors (ATRT). , 2019, Neuro-oncology.

[13]  Y. Arakawa,et al.  Clinical characteristics, treatment, and survival outcome in pediatric patients with atypical teratoid/rhabdoid tumors: a retrospective study by the Japan Children's Cancer Group. , 2019, Journal of neurosurgery. Pediatrics.

[14]  M. Aboian,et al.  High‐grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication—a comprehensive clinical, radiographic, pathologic, and genomic analysis , 2019, Brain pathology.

[15]  C. Sommer,et al.  Childhood supratentorial ependymomas with YAP1‐MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features , 2018, Brain pathology.

[16]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[17]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[18]  Sandhya Mangalore,et al.  Imaging characteristics of supratentorial ependymomas: Study on a large single institutional cohort with histopathological correlation , 2015, Asian Journal of Neurosurgery.

[19]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[20]  T. Pietsch,et al.  Bone Involvement in Atypical Teratoid/Rhabdoid Tumors of the CNS , 2013, American Journal of Neuroradiology.

[21]  B. Jin,et al.  MRI features of atypical teratoid/rhabdoid tumors in children , 2013, Pediatric Radiology.

[22]  S. Maier,et al.  Diffusion imaging of brain tumors , 2010, NMR in biomedicine.

[23]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[24]  J. Biegel,et al.  Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes. , 2006, AJNR. American journal of neuroradiology.

[25]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.